Home > Insider Trading > Filing (0001104659-23-100560)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1737953	Replimune Group Inc.	REPL	Biological Products, (No Disgnostic Substances) (2836)	822082553

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1744425	Pamela Esposito	C/O Replimune Group, Inc. 500 Unicorn Park Drive Woburn MA 01801	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-09-11	5,358	$3.30	268,794	No	4	M	Direct
Common Stock	Disposition	2023-09-11	5,358	$20.01	263,436	No	4	S	Direct
Common Stock	Acquisiton	2023-09-12	300	$3.30	263,736	No	4	M	Direct
Common Stock	Disposition	2023-09-12	300	$20.00	263,436	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-09-11	5,358	$0.00	5,358	$3.30
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-09-12	300	$0.00	300	$3.30

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
86,333		2027-07-26	No	4	M	Direct
86,033		2027-07-26	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof.
The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.